Yuhan Corporation

Korea's big five pharma put 12.4% of sales into R&D, and three of them set it by formula

Combined first-half research spending reached 562.8 billion won. Chong Kun Dang's 37% jump supplied nearly 40% of the group's increase, and the filings carry no profit lines to weigh it against.